Trade Cassava Sciences Inc - SAVA CFD

Cassava Sciences Inc. Company profile

Cassava Science Inc is a clinical-stage biopharmaceutical company that specialises in detecting and treating Alzheimer’s disease, an incurable progressive neurologic disorder, which is . The company is listed on the Nasdaq under the ticker SAVA.

According to Cassava, over five million people in the US have Alzheimer’s. The company focuses on research and development to find new approaches for its treatment and diagnosis. 

Cassava is developing Simufilam for the proposed treatment of Alzheimer's. According to the company, Simufilam is a proprietary oral drug candidate, developed in-house with academic collaborators. Simufilam, or PTI-125, is the company’s lead therapeutic product candidate. It’s currently (17 March) undergoing Phase 3 clinical studies.

SavaDx is the company’s investigational diagnostic for Alzheimer’s. According to the company, SavaDx is being developed to detect the disease with a simple blood test. However, SavaDx is still an early-stage product candidate and a lower priority than Simufilam, Cassava said.

Cassava was incorporated in 1998. It’s based in Austin, Texas, US. Remi Barbier has served as president, CEO and chairman of the board of directors since the company’s inception. Nadav Friedmann is the company’s chief medical officer. James Kupiec is the chief clinical development officer.